Results 41 to 50 of about 9,770,551 (325)

Sex and ethnicity in early‐onset Alzheimer's disease biomarkers and global function

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Early‐onset Alzheimer's disease (EOAD) may have distinct biomarker and clinical features from late‐onset AD (LOAD). EOAD is understudied in ethnically heterogeneous populations. METHODS We studied EOAD (N = 44, age 64.7 ± 5.5, 55% female, 52%
Breton M. Asken, Wei‐En Wang, Franchesca Arias, Shellie‐Anne Levy, Warren W. Barker, Monica Rosselli, Rosie Curiel Cid, Michael Marsiske, Melissa J. Armstrong, David E. Vaillancourt, David A. Loewenstein, Glenn E. Smith, Ranjan Duara   +12 more
doaj   +1 more source

Visualization of PS/γ-Secretase Activity in Living Cells

iScience, 2020
Summary: A change in Presenilin (PS)/γ-secretase activity is linked to essential biological events as well as to the progression of many diseases. However, not much is known about how PS/γ-secretase activity is spatiotemporally regulated in cells. One of
Masato Maesako, Nicole M. Sekula, Anna Aristarkhova, Polina Feschenko, Lauren C. Anderson, Oksana Berezovska   +5 more
doaj   +1 more source

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231.
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco   +27 more
doaj   +1 more source

Brain transcriptomes of zebrafish and mouse Alzheimer's disease knock-in models imply early disrupted energy metabolism

Disease Models & Mechanisms, 2022
Energy production is the most fundamentally important cellular activity supporting all other functions, particularly in highly active organs, such as brains.
Karissa Barthelson, Morgan Newman, Michael Lardelli   +2 more
doaj   +1 more source

Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in alzheimer’s disease and parkinson’s disease [PDF]

, 2017
Alzheimer's disease and Parkinson's disease are two common neurodegenerative diseases of the elderly people that have devastating effects in terms of morbidity and mortality.
Chakrabarti, S., Chatterjee, U., Ganguly, G., Saso, L.   +3 more
core   +3 more sources

CCT4 promotes tunneling nanotube formation

FEBS Letters, EarlyView.
Tunneling nanotubes (TNTs) are membranous tunnel‐like structures that transport molecules and organelles between cells. They vary in thickness, and thick nanotubes often contain microtubules in addition to actin fibers. We found that cells expressing monomeric CCT4 generate many thick TNTs with tubulin.
Miyu Enomoto, Akiko Asada, Taro Saito, Kanae Ando   +3 more
wiley   +1 more source

Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Commercially available plasma p‐tau217 biomarker tests are not well studied in ethnically diverse samples. METHODS We evaluated associations between ALZPath plasma p‐tau217 and amyloid‐beta positron emission tomography (Aβ‐PET) in Hispanic ...
Breton M. Asken, Jesse C. DeSimone, Wei‐En Wang, Karen N. McFarland, Franchesca Arias, Shellie‐Anne Levy, Jacob Fiala, Idaly Velez‐Uribe, Robin P. Mayrand, Luana Okino Sawada, Christian Freytes, Michael Adeyosoye, Warren W. Barker, Elizabeth A. Crocco, Steven T. DeKosky, Malek Adjouadi, Monica Rosselli, Michael Marsiske, Melissa J. Armstrong, Glenn E. Smith, Rosie Curiel Cid, David A. Loewenstein, David E. Vaillancourt, Ranjan Duara   +23 more
doaj   +1 more source

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress.
Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group   +15 more
doaj   +1 more source

2024 Alzheimer's disease facts and figures

Alzheimer's & Dementia
This article describes the public health impact of Alzheimer's disease (AD), including prevalence and incidence, mortality and morbidity, use and costs of care and the ramifications of AD for family caregivers, the dementia workforce and society.

semanticscholar   +1 more source

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source